Boston Scientific’s Drug-Eluting Stent Receives FDA Approval

The FDA approved Boston Scientific’s premarket approval application for its Eluvia drug-eluting vascular stent system.

The device is developed to treat peripheral artery disease by using a drug-polymer combination to continually release paclitaxel over one year.

It is designed to stop tissue from regrowing that may become an obstruction for the stented artery.